The inter-ministerial panel, headed by Economic Affairs Secretary Shaktikanta Das, has approved Rs 420 crore FDI proposal of Advanced Enzyme Technologies which intends to sell its stake to foreign investors by making fresh issuance of shares.
FIPB has also given its approval to Corona Remedies Private's investment worth Rs 118 crore. The company had sought approval for foreign investment of 19.51 per cent by Mauritius-based Cydista, a Finance Ministry statement said.
The board also cleared proposals of Macmillan Publishers International and Ordain Health Care Global, entailing investment flow of Rs 28.20 crore and Rs 77.05 crore, respectively.
Also, eight proposals including that of IBM India, Janalakshmi Financial Services, Tikona Digital Networks and Oxigen Services were deferred.
FIPB can clear FDI proposals envisaging investment of up to Rs 5,000 crore and those involving higher investment are approved by the Cabinet Committee on Economic Affairs (CCEA).
FDI in most sectors are allowed through an automatic route but in certain sectors proposals have to go through the FIPB.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
